Since the development of tyrosine kinase inhibitors (TKIs), which bind to the BCR::ABL1 kinase and thereby inhibit downstream target phosphorylation, CML can be effectively treated resulting in overall 10-year survival rates reaching 83% (Hochhaus et al., 2017). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.